Implantica Submits Final FDA Response for RefluxStop® Approval, Aiming for U.S. Market Entry

Implantica's Ambitious Step towards Market Approval

Implantica AG, a pioneering medtech company based in Liechtenstein, is making significant strides in the medical field with its innovative device, RefluxStop®, intended for the treatment of gastroesophageal reflux disease (GERD). As of May 20, 2026, the company announced the submission of its final response to the U.S. Food and Drug Administration (FDA) regarding the Premarket Approval (PMA) application for RefluxStop®.

The submission arrives after a meticulous review and involves comprehensive answers to the FDA's inquiries. This includes fulfilling additional testing requirements requested in prior FDA comments and undergoing a rigorous evaluation involving three PMA modules and several pre-approval inspections. Impressively, all six pre-approval inspections, covering manufacturing sites, quality systems, and clinical trial inspections, were concluded favorably, solidifying Implantica’s path toward gaining FDA approval.

Dr. Peter Forsell, the founder, CEO, and inventor of RefluxStop®, expressed profound gratitude for the FDA's comprehensive review process. In his statement, he emphasized the importance of this milestone, highlighting years of dedicated work encompassing clinical, scientific, regulatory, and operational dimensions. His optimism is further fueled by the strong support and interest the device has garnered from leading surgeons and gastroenterologists.

RefluxStop® stands out due to its unique design aimed at addressing acid reflux—a condition affecting roughly 1 billion people worldwide—by restoring the body’s natural anatomy without constraining the food passageway. Unlike traditional surgical methods, which often lead to significant side effects such as swallowing difficulties, RefluxStop® preserves the lower esophageal sphincter's natural functionality, thereby enhancing patient comfort and reducing post-surgery complications.

The PMA application is underpinned by rich long-term clinical data, including a pivotal clinical study with a five-year follow-up mandated by the FDA. This study has demonstrated exceptional safety and efficacy outcomes, corroborated by multiple peer-reviewed publications. Dr. Forsell notes that the robust clinical evidence showcased through various studies strengthens the company's confidence in RefluxStop®'s potential impact on surgical treatments for GERD in the U.S.

As the PMA review process progresses, Implantica remains optimistic about bringing RefluxStop® to patients across America, marking a transformative shift in GERD treatment methodologies. The anticipation surrounding the device reveals a considerable shift towards innovative healthcare solutions that prioritize patient care and minimize surgical risks. As the next steps unfold, all eyes will be on the FDA's decision regarding this groundbreaking technology.

The Future of Implantica and RefluxStop®

Implantica is steadfast in its commitment to advancing healthcare solutions through innovative technology. The company boasts a comprehensive product pipeline supported by two key platform technologies. These innovations include an eHealth platform, which allows for remote monitoring and communication with implants, and a wireless energizing platform that powers the devices through intact skin. Such technological advancements are not only poised to enhance patient outcomes but also aim to reduce healthcare costs in the long term.

The future of RefluxStop® seems promising, with an increasing demand for alternative treatments to GERD that avoid the classic pitfalls of conventional surgeries. Implantica's emphasis on patient safety and comfort may very well reshape the landscape of anti-reflux surgery in the years to come. Keeping up with the latest news and updates from Implantica, interested parties can visit their official website or contact their corporate affairs team directly.

For further inquiries, please reach out to Nicole Pehrsson, Chief Corporate Affairs Officer, via phone at +41 (0)43 505 20 57 or [email protected]

As the story unfolds, it remains crucial for stakeholders, patients, and medical professionals to stay tuned for the results of the FDA's review process, which could open new avenues for treating this common affliction widely affecting the global population.